Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Capecitabine
Drug ID BADD_D00349
Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indications and Usage For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Marketing Status Prescription
ATC Code L01BC06
DrugBank ID DB01101
KEGG ID D01223
MeSH ID D000069287
PubChem ID 60953
TTD Drug ID D00HCQ
NDC Product Code 72205-007; 69097-948; 59923-722; 59651-204; 0378-2511; 55111-893; 55111-496; 0054-0272; 72205-006; 70756-816; 50268-154; 51407-095; 15308-0714; 16714-467; 62756-239; 67877-458; 64980-277; 55512-0015; 16729-072; 68001-487; 67877-459; 55111-497; 51079-510; 35369-0010; 54893-0002; 70756-815; 63482-099; 60687-149; 0004-1101; 62331-043; 72485-205; 53183-4009; 69539-019; 0004-1100; 65162-843; 16729-073; 72969-094; 62756-238; 16714-468; 68554-0033; 69097-949; 54245-7014; 72485-204; 62756-088; 0054-0271; 59651-205; 0093-7473; 72606-555; 76302-001; 69539-020; 65162-844; 53104-7618; 0378-2512; 51407-096; 81955-0001; 63759-0001; 49452-1713; 68001-488; 65129-1241; 64980-276; 0093-7474; 72606-554; 59923-721
Synonyms Capecitabine | N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine | Xeloda
Chemical Information
Molecular Formula C15H22FN3O6
CAS Registry Number 154361-50-9
SMILES CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.021--Not Available
Medication residue present13.15.01.032--Not Available
Candida infection11.03.03.0210.001865%
Aspergillus infection11.03.01.0040.000278%Not Available
Immune thrombocytopenic purpura01.08.01.007; 10.04.01.0080.000799%Not Available
Language disorder19.19.01.006; 17.02.08.0150.000799%Not Available
Mouth swelling23.04.01.020; 10.01.05.020; 07.05.04.0070.000799%Not Available
Perforation08.01.03.0580.000208%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.001737%
Anal incontinence17.05.01.021; 07.01.06.029--
Persistent depressive disorder19.15.01.0060.000533%Not Available
Somatic symptom disorder19.24.01.006--Not Available
Adenocarcinoma of colon16.13.01.010; 07.21.01.0080.000799%Not Available
Breast cancer recurrent21.05.01.017; 16.10.01.0090.000278%Not Available
Carcinoembryonic antigen increased13.22.01.0090.000533%Not Available
Computerised tomogram abnormal13.18.03.0020.000799%Not Available
Coombs negative haemolytic anaemia01.06.03.0010.000533%Not Available
Cystitis radiation20.03.02.009; 12.05.02.0090.000533%Not Available
Full blood count decreased13.01.07.004--Not Available
Gastroenteritis radiation12.05.02.010; 07.08.03.0150.000533%Not Available
Hand-foot-and-mouth disease23.09.03.012; 11.05.08.004; 07.05.07.0160.000533%Not Available
Malignant ascites16.32.03.013; 07.07.01.0040.000208%Not Available
Metastases to bone16.22.02.005; 15.09.03.0060.003197%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.000208%Not Available
Obstruction gastric07.13.04.0020.000799%
Pancreatic carcinoma metastatic16.13.10.003; 07.21.09.0060.000208%Not Available
Periportal sinus dilatation24.03.03.037; 09.01.06.0200.000533%Not Available
Radiation proctitis07.08.04.003; 12.05.02.0120.001332%Not Available
Rectal perforation07.04.01.0040.000799%
Recurrent cancer16.16.01.0150.000799%Not Available
The 33th Page    First    Pre   33 34 35    Next   Last    Total 35 Pages